Topic: non-Hodgkin lymphoma
All eyes are on Roche as the first biosimilar rival to big-selling lymphoma blockbuster Rituxan won FDA approval.
The first dual PI3K-delta/gamma inhibitor will go up against Gilead's Zydelig, the first PI3K inhibitor, and Bayer’s Aliqopa.
Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.
England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.
Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.
Kyowa is also testing the drug in early-phase trials for solid tumors, in combo with its own IDO inhibitor KHK2455, BMS’ Opdivo and AZ’s Imfinzi.
Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.
J&J and AbbVie’s Imbruvica hasn’t run into many stumbling blocks. But it has hit one in non-Hodgkin lymphoma.
Imbruvica is the only treatment for Waldenström's macroglobulinemia patients. But before competition hits, its makers are pushing for a wider market.